A CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) TRIGGERED BY PNEUMONIA WITH DIAGNOSTIC DIFFICULTY

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
A CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) TRIGGERED BY PNEUMONIA WITH DIAGNOSTIC DIFFICULTY

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Kei
Omori
Kei Omori 1998go258@gmail.com SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan *
Yasuhiro Mochida yasuhiromochida@gmail.com SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Chika Shibuya e173039g@yokohama-cu.ac.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Mizuki Yamano mizukiymn@yahoo.co.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Kunihiro Ishioka kunihiro.ishioka@tokushukai.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Machiko Oka m_oka@shonankamakura.or.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Kyoko Maesato kyoukom7112@gmail.com SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Takayasu Ohtake ohtake@shonankamakura.or.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Yusuke Tsukamoto jinzou.net@gmail.com SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Sumi Hidaka s_hidaka@shonankamakura.or.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
Shuzo Kobayashi shuzo@shonankamakura.or.jp SHONAN KAMAKURA GENERAL HOSPITAL Kidney Disease and Transplant Center Kamakura-shi Japan -
 
 
 
 

 Thrombotic thrombocytopenic purpura(TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia caused by disseminated microvascular platelet-rich thrombi.The incidence of TTP is approximately 3.7 cases per 1,000,000 people.TTP is specifically associated with severe deficiency in ADAMTS13 activity. A study reported that  among 772 patients with a first episode of TMA diagnosed as TTP,  166  patients(28%) had acquired TTP of unknown cause, defined as the absence of detectable anti-ADAMTS13 IgG and no ADAMTS13 mutations. Acquired TTP of unknown cause has been associated with a variety of factors, including idiopathic cases, autoimmune disease, infections, pregnancy, cancer, HIV, transplantation and drugs.

We present a rare case of an elderly patient who developed TTP without detectable anti-ADAMTS13 IgG, triggered by pneumonia, advanced age, infection, and multiple myeloma,along with a review of the literature.  



Case:A 93-year-old man

Chief Complaint:Fever and coughPresent Illness:

A 93-year-old man developed fever 12 days before admission and was hospitalized with a diagnosis of aspiration pneumonia. On admission, his serum creatinine was 0.91 mg/dL and platelet count was 24,000/μL. The following day, schistocytes appeared on peripheral smear, renal function worsened (creatinine 1.10 mg/dL), and cerebral infarction developed. With a PLASMIC score of 6, thrombotic thrombocytopenic purpura (TTP) was suspected. Plasma exchange (PE) and three days of steroid pulse therapy were initiated, followed by oral prednisolone 50 mg/day. ADAMTS13 activity was subsequently found to be markedly reduced (<1%), confirming the diagnosis of TTP (ADAMTS13 inhibitor negative)

After five PE sessions, platelet count improved to 270,000/μL and PE was discontinued. However, platelet count later declined again. Since ADAMTS13 activity remained normal, TTP relapse was considered unlikely. Repeat PE showed minimal response, and platelet transfusions were given as supportive therapy. Bone marrow examination revealed multiple myeloma (MM) with monoclonal kappa light chain, which was considered to contribute to thrombocytopenia in addition to TTP.By the way, inhibitor and genetic abnormalities were negative.

We report a rare case of TTP triggered by pneumonia in an elderly patient, in whom MM was later diagnosed. A combination of factors—advanced age, infection, and multiple myeloma—may have contributed to decreased ADAMTS13 activity and the development of TTP.

Kewords